agilon health, inc. (AGL)
| Market Cap | 1.64B +257.3% |
| Revenue (ttm) | 5.92B +0.3% |
| Net Income | -232.22M |
| EPS | -13.97 |
| Shares Out | 16.79M |
| PE Ratio | n/a |
| Forward PE | 77.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,511 |
| Open | 96.42 |
| Previous Close | 96.86 |
| Day's Range | 95.25 - 99.75 |
| 52-Week Range | 7.48 - 133.04 |
| Beta | 3.05 |
| Analysts | Hold |
| Price Target | 110.92 (+13.31%) |
| Earnings Date | Aug 5, 2026 |
About AGL
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Westerville, Ohio.
Financial Performance
In 2025, agilon health's revenue was $5.93 billion, a decrease of -2.11% compared to the previous year's $6.06 billion. Losses were -$391.35 million, 50.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for AGL stock is "Hold." The 12-month stock price target is $110.92, which is an increase of 13.31% from the latest price.
News
Agilon Health price target raised to $146 from $141 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Agilon Health (AGL) to $146 from $141 and keeps an Overweight rating on the shares. The firm says results…
Citi upgrades Agilon Health to Neutral with Sell thesis played out
Citi analyst Daniel Grosslight upgraded Agilon Health (AGL) to Neutral from Sell with a price target of $115, up from $105. The firm updated its ratings and targets in the…
Agilon Health upgraded to Neutral from Sell at Citi
Citi upgraded Agilon Health (AGL) to Neutral from Sell with a $115 price target
Agilon Health price target raised to $116 from $35 at Baird
Baird analyst Michael Ha raised the firm’s price target on Agilon Health (AGL) to $116 from $35 and keeps a Neutral rating on the shares.
Agilon Health price target raised to $140 from $95 at Benchmark
Benchmark raised the firm’s price target on Agilon Health (AGL) to $140 from $95 and keeps a Buy rating on the shares.
Agilon Health price target raised to $112 from $67 at Truist
Truist analyst Jailendra Singh raised the firm’s price target on Agilon Health (AGL) to $112 from $67 and keeps a Hold rating on the shares.
Agilon Health price target raised to $125 from $120 at Evercore ISI
Evercore ISI raised the firm’s price target on Agilon Health (AGL) to $125 from $120 and keeps an In Line rating on the shares.
Agilon Health price target raised to $111 from $81 at Barclays
Barclays raised the firm’s price target on Agilon Health (AGL) to $111 from $81 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says…
Agilon Health reports Q2 EPS $1.04, consensus 27c
Reports Q2 revenue $1.49B, consensus $1.45B. “Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon’s strategic initiatives and reinforcing our confiden...
Agilon Health sees Q3 revenue $1.445B-$1.475B, consensus $1.41B
Sees Q3 adjusted EBITDA ($5M)-$5M
agilon health Earnings Call Transcript: Q2 2026
Second quarter results exceeded guidance, driven by improved risk adjustment, disciplined cost management, and operational execution. Full-year 2026 guidance was raised, with strong liquidity and continued investment in AI and clinical pathways supporting future growth.
agilon health Earnings release: Q2 2026
agilon health released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
agilon health Quarterly report: Q2 2026
agilon health has published its Q2 2026 quarterly earnings report on August 5, 2026.
agilon health Reports Second Quarter 2026 Results
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the second quart...
Did agilon health, inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Citi downgrades Agilon Health to Sell on ‘too rich’ valuation
Citi analyst Daniel Grosslight downgraded Agilon Health (AGL) to Sell from Neutral with a price target of $105, up from $80. The firm sees a less favorable risk/reward following the…
Agilon Health downgraded to Sell from Neutral at Citi
Citi analyst Daniel Grosslight downgraded Agilon Health (AGL) to Sell from Neutral with a $105 price target
Agilon Health price target raised to $141 from $72 at Wells Fargo
Wells Fargo raised the firm’s price target on Agilon Health (AGL) to $141 from $72 and keeps an Overweight rating on the shares. The firm’s outlook for Healthcare Services earnings…
Agilon Health says REACH ACOs achieved $229M in gross savings in 2024
agilon health (AGL) announced that its Accountable Care Organizations achieved $229M in gross savings, including $54M savings in the Medicare Trust Fund, during the 2024 performance year of the ACO…
agilon health Reports ACO REACH Model Results for 2024 Performance Year
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that its Accountable Care Organiza...
agilon health Sets Date to Report Second Quarter 2026 Financial Results
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financi...
agilon health to Participate in Upcoming Conferences
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that members of its manageme...
agilon health Transcript: AGM 2026
The meeting focused on strategic priorities, board alignment, and operational execution, with all director nominees reelected, auditor ratified, and executive compensation approved. No shareholder questions were raised, and risks were referenced per SEC filings.
Agilon Health upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Andrew Mok upgraded Agilon Health (AGL) to Equal Weight from Underweight with an $81 price target The firm says the outlook for value-based care has “materially improved in…
Agilon Health price target raised to $95 from $13 at Benchmark
Benchmark analyst Bill Sutherland raised the firm’s price target on Agilon Health (AGL) to $95 from $13 and keeps a Buy rating on the shares. Following “remarkable” year-to-date performance, the…